Idorsia Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDRSF research report →
About the company
Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc.
- CEO
- Jean-Paul Clozel
- IPO
- 2017
- Employees
- 1,100
- HQ
- Allschwil, CH
Price Chart
- Market Cap
- $1.89B
- P/E
- -7.01
- P/S
- 6.50
- P/B
- -1.42
- EV/EBITDA
- -18.44
- Div Yield
- 0.00%
- Gross Margin
- 87.88%
- Op Margin
- -95.64%
- Net Margin
- -100.74%
- ROE
- 19.23%
- ROIC
- -59.30%
- Revenue
- $221.11M · 96.52%
- Net Income
- $-112,053,693 · 57.52%
- EPS
- $-0.52 · 64.14%
- Op Income
- $-116,381,000
- FCF YoY
- 56.97%
- 52W High
- $7.70
- 52W Low
- $2.40
- 50D MA
- $5.76
- 200D MA
- $4.95
- Beta
- 1.67
- Avg Volume
- 2.30K
Get TickerSpark's AI analysis on IDRSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IDRSF coverage
Recent articles, reports, and earnings notes.
No research on IDRSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IDRSF report →Similar companies
Peers in the same neighborhood.